

## REMARKS

Claims 1-40 are pending in the current application. Claims 1-36 and 39 have been allowed. Claims 37, 38 and 40 are rejected. Claims 37, 38 and 40 are herein amended to bring them into condition for allowance. No new matter is introduced in the present amendments.

Claim 40 is rejected under 35 U.S.C. § 112, first paragraph, because the specification while enabling for a pharmaceutical composition for treating a disease mediated by HIV-1 in a host, does not reasonably provide enablement for treating mediated by human immunodeficiency or inhibit HIV generally

References to human immunodeficiency virus and HIV have been deleted from claim 40. The Examiner has indicated in the Office Action that no limitation to a particular use is required.

Claims 37, 38 and 40 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 37 was rejected as improperly dependent on claim 32. Claim 37 is herein amended to be dependent on claim 1.

Claim 38 was rejected as lacking sufficient antecedent basis because it recites the limitation "A method according to claim 37 wherein the host is infected...". Claim 37 does not recite the term host. The phrase "host is infected with a strain of HIV-1 expressing a" was deleted and the claim now reads "the reverse transcriptase contains at least one mutation...". The claim now has sufficient antecedent basis in claim 37.

Claim 40 was rejected because the phrase "for treating diseases mediated by human immunodeficiency virus inhibit HIV" was unclear. The incorrect phrase was deleted in the amendment previously noted for claim 40.

**CONCLUSIONS**

Applicants believe that all claims are now in condition for allowance and withdrawal of the remaining rejections and allowance of the amended claims is respectfully requested. No other fees are believed to be required, but in the event a fee is required, the Examiner is authorized to charge our deposit account number 18-1700 the requisite fee.

Respectfully submitted,



Brian L. Buckwalter  
Agent for Applicant  
Registration No. 46,585

October 31, 2006  
Roche Palo Alto LLC  
3431 Hillview Avenue,  
Palo Alto, CA 94304-1397  
Telephone 650-855-6995  
Telecopier 650-855-5322